Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MZeDT3 is a first-in-class, highly selective Proteolysis Targeting Chimera (PROTAC) designed to induce the degradation of ZAKα (MAP3K20), a key kinase involved in the ribotoxic stress response (RSR). ZAKα acts as a sensor for stalled ribosomes, triggering downstream signaling pathways like p38 and JNK MAP kinases in response to various stressors, including UV radiation and ribotoxic toxins. MZeDT3 consists of a ZAKα-binding ligand (based on the scaffold of the kinase inhibitor MZe786) linked to a von Hippel-Lindau (VHL) E3 ligase recruiter. By depleting ZAKα protein levels, MZeDT3 effectively blocks the RSR, providing a powerful tool for studying the biological roles of ZAKα and potentially serving as a lead compound for treating diseases driven by aberrant RSR signaling, such as UV-induced skin damage or metabolic stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MZeDT3.